Sorcero

Reading and synthesizing across a reported 263 million publications and 1.3 billion citations plus congress sessions, safety cases, and medical inquiries is a task with no manual equivalent; the platform exists because the volume defeats human review. Natural language processing tuned to medical literature is the product rather than a feature on a workflow tool.

Adoption is credible and consistently reported at a third to 40 percent of the top 30 global pharmaceutical companies, with workshop participation from Amgen, Biogen, Lundbeck, and argenx. Third party positioning is stronger than most: CB Insights names the company a Leader in AI enabled pharmacovigilance software alongside IQVIA, Veeva, and Oracle, which is notable for a company of this size, and it holds a 2025 Google Cloud Partner of the Year award. Held back from A because headline efficiency figures, 18x faster insights and 70 percent time saved, are vendor and customer stated without published methodology or baseline.

The company names hallucination prevention as an explicit platform property alongside validated outputs and regulatory safeguards, and describes an agentic architecture in which specialized agents validate medical information rather than a single model generating answers. That is the correct concern to foreground: in medical affairs and pharmacovigilance a fabricated citation or missed adverse event signal has regulatory consequence. A customer quote in the company's own materials is telling about how this is used in practice, describing getting an answer in two minutes and then spending thirty minutes checking the references. Held back from A because no measured hallucination or accuracy rate was published, and the operative work here is public literature rather than patient data.

Not an EHR integration story, correctly, since the buyer is a pharmaceutical organization. Integration breadth is instead across life sciences data sources: public literature and citation databases, congress and abstract data, internal CRM systems, safety case records, and medical inquiry logs, with the Axiom acquisition adding medical device real world data. Combining public evidence with internal interaction data is the substantive capability. Held back from A because named source systems and integration methods were not retrieved.

No public pricing. Contact the vendor. Enterprise agreements with life sciences organizations. The company states it pairs the platform with high touch services including Insights Leads and Deployment Strategists, so this is a SaaS plus services engagement rather than pure licence, and buyers should establish the split since the services component typically drives adoption but also cost.

Bounded to the medical side of life sciences: medical affairs, scientific communications, publications, and pharmacovigilance, extended to medical device organizations through the Axiom Health acquisition. That scoping is what keeps it in this index, since medical affairs is a scientific exchange function subject to its own regulatory separation from commercial promotion. Buyers should note the platform also serves commercial teams, and that boundary is worth confirming in deployment.